Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Posted by Geri Gentry on Jul 28th, 2026

Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Get Free Report) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 239,118 shares, a decrease of 74.5% from the June 30th total of 938,810 shares. Based on an average trading volume of 1,138,425 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.1% of the company’s shares are sold short.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Allen Capital Group LLC bought a new position in Jupiter Neurosciences in the 4th quarter worth approximately $31,000. Yorkville Advisors Global LP acquired a new position in Jupiter Neurosciences in the fourth quarter worth approximately $135,000. Geode Capital Management LLC increased its holdings in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after buying an additional 28,826 shares in the last quarter. Finally, Vestor Capital LLC lifted its position in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the last quarter.

Jupiter Neurosciences Price Performance

NASDAQ JUNS opened at $0.11 on Tuesday. Jupiter Neurosciences has a 1-year low of $0.11 and a 1-year high of $1.84. The company has a market capitalization of $4.12 million, a P/E ratio of -0.42 and a beta of 1.73. The business has a 50 day moving average price of $0.22 and a 200 day moving average price of $0.42.

Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.23 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Jupiter Neurosciences

Jupiter Neurosciences Company Profile

(Get Free Report)

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.